The present invention relates to the treatment of cancer using combination therapy comprising a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), in combination with (i) a modulator of a protein kinase (PK) selected from an Epidermal Growth Factor inhibitor (EGFR inhibitor) and EGFR antibody； (ii) an inhibitor of mammalian target of rapamycin (m TOR)； (iii) a mitogen- activated protein kinase (MEK) inhibitor； (iv) a mutated B-Raf inhibitor； (v) a chemotherapeutic agent like Gemcitabine, 5-FU, Irinotecan and Oxaliplatin； and (vi) certain combinations thereof. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, m TOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The combination provides a therapeutic effect which is at least additive, and is preferably synergistic. The present invention further relates to the treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.La présente invention concerne le traitement du cancer au moyen d'une polythérapie comprenant un double modulateur du substrat récepteur de l'insuline (IRS) et du transducteur de signal et activateur de la transcription 3 (Stat3), en combinaison avec (i) un modulateur d'une protéine kinase (PK) sélectionné à partir d'un inhibiteur de facteur de croissance épidermique (inhibiteur EGFR) et d'un anticorps anti-EGFR； (ii) un inhibiteur de cible de la rapamycine chez les mammifères (mTOR)； (iii) un inhibiteur de protéine kinase activée par un agent mitogène (MEK)； (iv) un inhibiteur
